Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Sep;49(9):106945.
doi: 10.1016/j.ejso.2023.05.020. Epub 2023 Jun 12.

Trans oral robotic surgery for oropharyngeal cancer: A multi institutional experience

Armando De Virgilio  1 , Raul Pellini  2 , Giovanni Cammaroto  3 , Rossella Sgarzani  4 , Andrea De Vito  3 , Manlio Gessaroli  5 , Andrea Costantino  1 , Gerardo Petruzzi  6 , Bianca Maria Festa  1 , Flaminia Campo  6 , Claudio Moretti  7 , Barbara Pichi  6 , Giuseppe Mercante  1 , Giuseppe Spriano  1 , Claudio Vicini  8 , Giuseppe Meccariello  3
Affiliations
Multicenter Study

Trans oral robotic surgery for oropharyngeal cancer: A multi institutional experience

Armando De Virgilio et al. Eur J Surg Oncol. 2023 Sep.

Abstract

Objectives: Trans Oral Robotic Surgery (TORS) has proved to be a safe and feasible treatment for oropharyngeal squamous cell carcinoma (OPSCC). The aim of this study is to analyse oncological outcomes of OPSCC patients treated with TORS.

Materials and methods: This study involved 139 patients with OPSCC, treated with TORS between 2008 and 2020. Clinicopathological characteristics, treatment details and oncological outcomes were evaluated retrospectively.

Results: The management strategies included TORS alone in 42.5%, TORS-RT in 25.2% and TORS-CRT in 30.9%. The ENE was noted in 28.8% of neck dissections. In 19 patients clinically classified as unknown primaries, the primary was found in 73.7%. Rates of local, regional relapses and distant metastasis were 8.6%, 7.2%, and 6.5%, respectively. The 5 year- Overall Survival and Disease Free Survival were 69.6% and 71.3%, respectively.

Conclusion: TORS fits well in the modern management of OPSCC. Although definitive CRT remains a milestone, TORS is proving to be a valid and safe treatment option. The choice of the therapeutic strategy requires evaluation by a multidisciplinary team.

Keywords: Cancer; Chemotherapy; Oropharyngeal; Outcomes; Quality of life; Radiotherapy; Survival; Trans oral robotic surgery.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Claudio Vicini is consultant and proctor for Intuitive Surgical Inc. Giuseppe Meccariello has nothing to declare. Manlio Gessaroli has nothing to declare. Raul Pellini has nothing to declare. Andrea De Vito has nothing to declare. Rossella Sgarzani has nothing to declare. Armando De Virgilio has nothing to declare. Andrea Costantino has nothing to declare. Flaminia Campo has nothing to declare. Giovanni Cammaroto has nothing to declare. Gerardo Petruzzi has nothing to declare. Bianca Festa has nothing to declare. Claudio Moretti has nothing to declare. Giuseppe Mercante has nothing to declare. Barbara Pichi has nothing to declare. Giuseppe Spriano has nothing to declare.

Publication types

MeSH terms